Press Release

Florham Park, NJ, April 5th, 2024

Xiromed LLC today announced the launch of Guanfacine Tablets, 1mg and 2mg strengths, generic to Tenex®.  Xiromed’s product will be available in 100 count bottles.          

Annual sales for Tenex® and its generics for the 12-month period ending in January, 2024 were $35m, according to IQVIA, a leading healthcare data and analytics provider.    

Xiromed CEO Rob Spina commented, “Xiromed continues to bring affordable generic options to market for U.S. patients.  The launch of Guanfacine tablets bolsters our portfolio of high-quality generic medicines as we continue to expand Xiromed’s footprint in the U.S. pharmaceutical market.”   

Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain.  Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market.  In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products.  Learn more at http://www.xiromed.com/usa/